The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Natural Killer Cell Therapies: Pipeline Review

  • Lowest Price Guaranteed From USD 1,299

  • Published
    June 2019

  • Pages
    80

  • View Count
    2233

Example Insights

 

 

Overview

Natural killer (NK) cells, or killer (K) cells, represent an important subset of cellular mediators of the innate immune system. These cells are known to be instrumental in containing viral infections and regulating tumor development, while the adaptive immune system generates an antigen-specific response.  Technically, they are classified as group I innate lymphocytes. Although they share a common progenitor, NK cells are very different from B-lymphocytes and T-lymphocytes,  and do not require specific antigen-based activation in order to function. The cytotoxic effects of these cells are mediated using perforin and granzymes, which is somewhat similar to the mode of action of cytotoxic T cells. Additionally, studies have demonstrated that NK cells can also secrete certain cytokines and chemokines, such as IFNγ and TNFα, through which they can recruit other immune components to augment and sustain an immune response. For instance, IFNγ secreted by NK cells has been shown to be involved in T-helper (TH1) cell based immune response, and the activation of certain antigen-presenting cells and macrophages. Alternatively, NK cells have been shown to respond to certain types of interferons and macrophage-derived cytokines.  

Several studies have demonstrated the various benefits of NK cells as a therapeutic tool. Currently, these cells are being evaluated across multiple clinical trials to treat various types of cancer and infectious diseases. Further, the genetic modification of NK cells has demonstrated additional benefits, and many companies are also working on developing allogenic product candidates that can be used as off-the-shelf therapies.

Scope of the Report

The “Natural Killer Cell Therapies: Pipeline Review” report features an extensive study of the current market landscape and clinical research scenario related to all NK cell-based products / product candidates. The information in this report has been presented in the form of interactive dashboards, aiming to provide a comprehensive overview of the ongoing activity in this domain, and offering insights on a number of important parameters, including:

  • An analysis of the contemporary developer landscape, providing information on key innovator companies and their respective NK cell therapies, current (highest) phase of development, source of NK cells (autologous and allogenic), target disease indication (hematological malignancies, solid tumors and others), type of therapy (monotherapy and combination therapy), route of administration and other relevant details (if available).
  • Analysis of both completed and active clinical trials, initiated from January 2009, featuring details on (primary) developer company (year of establishment, location of headquarters, and company size), type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), and other trial related details (collaborating sponsors, trial title, study objectives, location of trial, current status, availability of results, target therapeutic indication, study type, current / anticipated enrolment, study start / end date and key outcomes / results).
  • Analysis of terminated clinical trials, highlighting the developer company, type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), other trial related details (collaborating sponsors, trial title, study objectives, target therapeutic indication and study type) and reason for termination.

All information has been sourced and analyzed from company websites, press releases, reliable clinical trial data repositories (such as clinicaltrials.gov), and other publicly available information platforms.

Contents

Dashboard Outlines

Dashboard 1 is an interactive MS Excel dashboard that provides a detailed review of the contemporary developer landscape, featuring the identities and details of various innovator companies and their respective NK cell therapy candidates. The dashboard offers insights on current (highest) phase of development, source of NK cells (autologous and allogenic), target disease indication (hematological malignancies, solid tumors and others), type of therapy (monotherapy and combination therapy), route of administration and other relevant details (wherever available).

Dashboard 2 is an interactive MS Excel dashboard featuring an analysis of both completed and active clinical trials, which were registered starting from January 2009 to May 2019, featuring detailed charts on (primary) developer company (year of establishment, location of headquarters, and company size), type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), and other trial related details (collaborating sponsors, trial title, study objectives, location of trial, current status, availability of results, target therapeutic indication, study type, current / anticipated enrolment, study start / end date and key outcomes / results).

Dashboard 3 is another interactive MS Excel dashboard that offers a retrospective analysis of the various clinical development programs of NK cell based therapies clinical trials that have been discontinue for various reasons (highlighted wherever available). It is worth mentioning that in this analysis we have we have designated the “unknown” status to certain clinical development program that have not been updated from a long time, assuming that such trials are either terminated or indefinitely suspended. The analysis presented in this dashboard has been based on the identity and key details of developer company, (such as type of developer, geographical location), name of therapy, source of NK cells (autologous and allogenic), other trial related details (collaborating sponsors, trial title, study objectives, target therapeutic indication and study type) and reason for termination (wherever available).

Table of Contents

1. Introduction and Scope

2. Developer Landscape
2A. Developer Landscape: Analysis by Location of Headquarters
2B. Developer Landscape: Analysis by Phase of Development
2C. Developer Landscape: Analysis by Target Disease Indication
2D. Developer Landscape: Analysis by Source of NK Cells
2E. Developer Landscape: Analysis by Type of Therapy
2F. Developer Landscape: Analysis by Route to Administration
2G. Developer Landscape: Analysis by Year of Establishment (Industry Players)
2H. Developer Landscape: Analysis by Company Size (Industry Players)

3. Completed and Active Trials
3A. Clinical Trial Analysis: Analysis by Current Trial Status
3B. Clinical Trial Analysis: Analysis by Phase of Development
3C. Clinical Trial Analysis: Analysis by Availability of Results
3D. Clinical Trial Analysis: Analysis by Target Disease Indication
3E. Clinical Trial Analysis: Analysis by Source of NK Cells
3F. Clinical Trial Analysis: Analysis by Type of Therapy
3G. Clinical Trial Analysis: Analysis by Study Type
3H. Clinical Trial Analysis: Analysis of Enrolled Patient Population
3I. Clinical Trial Analysis: Analysis by Study Start / End Dates
3J. Geographical Location of Primary Sponsor
3K. Geographical Location of Completed / Active Trials

4. Terminated Trials
4A. Terminated Trials: Analysis by Reason for Termination
4B. Terminated Trials: Analysis by Phase of Development
4C. Terminated Trials: Analysis by Target Disease Indication
4D. Terminated Trials: Analysis by Source of NK Cells
4E. Terminated Trials: Analysis by Type of Therapy
4F. Terminated Trials: Analysis by Study Type

5. Appendix I: Dataset 1: Developer Landscape

6. Appendix II: Dataset 2: Completed / Active Clinical Research Trials

7. Appendix III: Dataset 3: Terminated Clinical Research Trials

8. Appendix IV: Dataset 4: Clinical Research, 2009-2019

9. Abbreviations

10. Sources and Bibliography

List of Figures

Figure 2.1. Developer Landscape: Distribution by Location of Headquarters
Figure 2.2. Developer Landscape: Distribution by Phase of Development 
Figure 2.3. Developer Landscape: Distribution by Target Disease Indication
Figure 2.4. Developer Landscape: Distribution by Source of NK Cells
Figure 2.5. Developer Landscape: Distribution by Type of Therapy
Figure 2.6. Developer Landscape: Distribution by Route to Administration
Figure 2.7. Developer Landscape: Distribution by Year of Establishment (Industry Players) 
Figure 2.8. Developer Landscape: Distribution by Company Size (Industry Players)
Figure 3.1. Clinical Trial Analysis: Distribution by Current Trial Status
Figure 3.2. Clinical Trial Analysis: Distribution by Phase of Development
Figure 3.3. Clinical Trial Analysis: Distribution by Availability of Results
Figure 3.4. Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 3.5. Clinical Trial Analysis: Distribution by Source of NK Cells
Figure 3.6. Clinical Trial Analysis: Distribution by Type of Therapy
Figure 3.7. Clinical Trial Analysis: Distribution by Study Type
Figure 3.7. Clinical Trial Analysis: Distribution of Enrolled Patient Population
Figure 3.7. Clinical Trial Analysis: Distribution by Study Start / End Dates
Figure 3.8. Geographical Location of Primary Sponsor
Figure 3.9. Geographical Location of Completed / Active Trials
Figure 4.1. Terminated Trials: Distribution by Reason for Termination
Figure 4.2. Terminated Trials: Distribution by Phase of Development 
Figure 4.3. Terminated Trials: Distribution by Target Disease Indication
Figure 4.4. Terminated Trials: Distribution by Source of NK Cells
Figure 4.5. Terminated Trials: Distribution by Type of Therapy
Figure 4.6. Terminated Trials: Distribution by Study Type

Listed Companies and Organizations

The following companies and organizations have been mentioned in the report.
 
  1. Allife Medical Science and Technology
  2. Anhui Provincial Hospital
  3. Asan Medical Center
  4. Baylor College of Medicine
  5. Capital Medical University
  6. Case Comprehensive Cancer Center
  7. Catholic University of Korea
  8. Cell Medica
  9. CellProtect Nordic Pharmaceuticals
  10. Celularity
  11. Chinese PLA General Hospital
  12. CiMass
  13. Cyto-Sen Therapeutics
  14. Cytovac
  15. Dresden University of Technology
  16. Duke University
  17. Fate Therapeutics
  18. First Hospital of Jilin University
  19. Fortress Biotech
  20. Fuda Cancer Hospital
  21. Gamida Cell
  22. GC PharmaGreen Cross Corporation
  23. Glycostem Therapeutics
  24. Gregorio Marañón Hospital
  25. Gruppo Italiano Malattie EMatologiche dell'Adulto
  26. Guangdong Provincial Hospital of Traditional Chinese Medicine
  27. Guangzhou Medical University
  28. Hangzhou Cancer Hospital
  29. Harbin Medical University
  30. Henan Cancer Hospital
  31. Hospital of Clinics of Porto Alegre
  32. Hospital Universitario La PazHospital La Paz
  33. iCell Gene Therapeutics
  34. Italian Group Hematological Diseases of the Adult
  35. Italian Sarcoma Group
  36. Ivy Life Sciences
  37. M.D. Anderson Cancer Center
  38. Mayo Clinic
  39. Medical College of Wisconsin
  40. Memorial Sloan Kettering Cancer Center
  41. Multimmune 
  42. NantKwest
  43. National Cancer Institute 
  44. National Defense Medical Center
  45. National University Hospital
  46. Niño Jesús University Children's HospitalHospital Niño Jesus
  47. Nkarta Therapeutics
  48. Nohla Therapeutics
  49. Paoli-Calmettes Institute
  50. PersonGen BioMedicineTherapeutics
  51. Pope John XXIII HospitalA.O. Ospedale Papa Giovanni XXIII
  52. Public Assistance - Hospitals of Paris
  53. Radboud University
  54. Sabz Biomedicals
  55. Samsung Medical Center
  56. Seoul National University Hospital
  57. Shanghai Houchao Biotechnology
  58. Shanghai iCELL Biotechnology
  59. Shanghai Public Health Clinical Center
  60. Shenzhen Hornetcorn Bio-technology Company
  61. Shenzhen Second People's Hospital
  62. SMT Bio
  63. Southwest Medical UniversityHospital, China
  64. St. Jude Children's Research Hospital
  65. Stanford University
  66. Sun Yat-sSen University
  67. Surface Oncology
  68. Tanta University
  69. The Catholic University of Korea
  70. The First People's Hospital of Changzhou
  71. University Hospital of, Basel
  72. University Hospital ofin Besançon
  73. University of Arkansas
  74. University of Minnesota
  75. University of Wisconsin
  76. Washington University School of Medicine
  77. Xuanwu Hospital
  78. Xuzhou Medical University
  79. Yonsei University
  80. Zumutor Biologics

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,299

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com